Year Published
- 2008 (0)
- (-) Remove 2009 filter 2009
- (-) Remove 2010 filter 2010
- (-) Remove 2011 filter 2011
- 2012 (2) Apply 2012 filter
- 2013 (0)
- 2014 (1) Apply 2014 filter
- 2015 (6) Apply 2015 filter
- 2016 (4) Apply 2016 filter
- 2017 (7) Apply 2017 filter
- (-) Remove 2018 filter 2018
- 2019 (1) Apply 2019 filter
- 2020 (0)
- 2021 (1) Apply 2021 filter
Research Topics
Populations
- Countries/Governments (0)
- Rural Populations (0)
- Smallholder Farmers (0)
- Women (0)
Types of Research
- Data Analysis (0)
- Literature Review (2) Apply Literature Review filter
- Portfolio Review (0)
- Research Brief (2) Apply Research Brief filter
Geography
- East Africa Region and Selected Countries (19) Apply East Africa Region and Selected Countries filter
- (-) Remove Global filter Global
- South Asia Region and Selected Countries (11) Apply South Asia Region and Selected Countries filter
- Southern Africa Region and Selected Countries (4) Apply Southern Africa Region and Selected Countries filter
- Sub-Saharan Africa (39) Apply Sub-Saharan Africa filter
- West Africa Region and Selected Countries (16) Apply West Africa Region and Selected Countries filter
Dataset
- ASTI (0)
- FAOSTAT (0)
- Farmer First (0)
- LSMS & LSMS-ISA (0)
- Other Datasets (0)
Current search
- (-) Remove 2010 filter 2010
- (-) Remove 2009 filter 2009
- (-) Remove 2018 filter 2018
- (-) Remove 2011 filter 2011
- (-) Remove Global filter Global
The private sector is the primary investor in health research and development (R&D) worldwide, with investment annual investment exceeding $150 billion, although only an estimated $5.9 billion is focused on diseases that primarily affect low and middle-income countries (LMICs) (West et al., 2017b). Pharmaceutical companies are the largest source of private spending on global health R&D focused on LMICs, providing $5.6 billion of the $5.9 billion in total private global health R&D per year. This report draws on 10-K forms filed by Pharmaceutical companies with the U.S. Securities and Exchange Commission (SEC) in the year 2016 to examine the evidence for five specific disincentives to private sector investment in drugs, vaccines and therapeutics for global health R&D: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed costs for research and manufacturing, and imperfect markets. 10-K reports follow a standard format, including a business section and a risk section which include information on financial performance, investment options, lines of research, promising acquisitions and risk factors (scientific, market, and regulatory). As a result, these filings provide a valuable source of information for analyzing how private companies discuss risks and challenges as well as opportunities associated with global health R&D targeting LMICs.
How development organizations, NGOs, and governments can best allocate scarce resources to those in need has long been debated. As opposed to universal allocation of resources, a more targeted approach attempts to minimize program costs while maximizing benefits among those with the greatest need or market opportunity. Many international development organizations strategically target clients based on geographic location (e.g., community, region, country) or socio-economic indicators, such as the World Bank’s “$1 a day” poverty line. Drawing on literature from several sectors, this brief presents additional methods of beneficiary targeting that international development organizations might consider. We find that beneficiary targeting/segmentation has the potential to make organizational and program efforts more equitable and efficient. With limited resources, smaller organizations have tended to use single robust indicators or simple heuristics, whereas agribusinesses and private sector firms have used more data-intensive marketing tools to position their products. Technological innovation and better access to data have made targeting more prevalent and potentially more affordable in agricultural development. However, creating valid and reliable target segments remains the most significant challenge.
This report presents data on selected agricultural commodities for the fourth quarter of 2009 (October through December 2009) and the months of January and February 2010, where available. More specifically, this report provides a summary of recent changes and trends in prices, demand, supply, and market conditions for key agricultural commodities. We find that agricultural commodity prices declined significantly in 2009 from peak 2008 levels. At the end of 2009, however, commodity prices began to rebound, which contributed to concerns over a possible return to high prices. In January and February, gains in the value of the U.S. Dollar helped keep agricultural commodity prices subdued.
Agriculture and Climate Change: Part I
With estimated global emissions of 5,969-6,615 metric tons (Mt) of carbon dioxide (CO2) per year, agriculture accounts for about 13.5% of total global anthropogenic emissions of greenhouse gases (GHG). Deforestation contributes about 11.8% of total GHG emissions, releasing about 5,800 Mt CO2 per year. Developing countries are largely responsible for emissions from agriculture and deforestation, with the developing countries of South Asia and East Asia accounting for 17% and 25% of global agricultural emissions respectively. Sub-Saharan Africa (SSA) accounts for about 13% of global emissions from agriculture and 15% of emissions from land use change and forestry. This report examines the biophysical and economic potential of mitigating agriculture and land use GHG emissions, and provides a summary on the current and projected impact of global carbon market mechanisms on emission reductions.
Agriculture and Climate Change: Part II
This report covers two topics related to agriculture and climate change in developing countries. The first section discusses the role of agricultural offsets in mitigating greenhouse gas emissions. Recent negotiations around a post-Kyoto Protocol agreement have included debate about whether agricultural carbon sequestration projects should be eligible under the Clean Development Mechanism (CDM). We examine the reasons for supporting or opposing this type of CDM reform and how these reasons relate to impacts on development goals and smallholder farmers, scientific uncertainty about carbon sequestration, and philosophical disagreement about the use of emission offsets. The second section covers proposed agricultural adaptation activities in Africa and other developing countries. While the majority of developing countries have outlined immediate adaptation needs in National Adaptation Programs of Action (NAPAs), few have made progress in implementing adaptation activities. We find that issues related to financial resources, scientific and technical information, and capacity building continue to challenge developing countries in preparing for the impacts of climate change.